Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hUC-MSC in Acute Cerebral Infarction
NCT03186456Phase 1Suspended
- Sponsor
- Sclnow Biotechnology Co., Ltd.
- Start
- Dec 2026
- Primary completion
- Jun 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in cerebral infarction comparing Group 1 (hUC-MSC + Aspirin) with Group 2 (Placebo + Aspirin) (2 arms). Primary endpoint: Treatment related-adverse events counting at 26 weeks. Planned start Dec 2026; status: suspended.
02
Drugs
human umbilical cord derived mesenchymal stem cells
03
Conditions
cerebral infarction
Beyond the preview
Go deeper on NCT03186456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03186456.